Private Wealth Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Private Wealth Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.98K	Hold	87	–	–	﹤0.01%	788
2026 Q1	$4.92K	Hold	87	–	–	﹤0.01%	783
2025 Q4	$5.17K	Hold	87	–	–	﹤0.01%	758
2025 Q3	$4.71K	Hold	87	–	–	﹤0.01%	754
2025 Q2	$4.78K	Hold	87	–	–	﹤0.01%	769
2025 Q1	$6.15K	Buy	+87	New	+$5.85K	﹤0.01%	704

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Private Wealth Asset Management's BMRN Position: Q2 2026 in Review

Private Wealth Asset Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 87 shares worth $4.98K. The position accounts for ﹤0.01% of the portfolio, ranked #788.

Private Wealth Asset Management first reported a position in BMRN in Q1 2025 and has held it in 6 quarters since. The position peaked at $6.15K in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Private Wealth Asset Management held 87 shares of BioMarin Pharmaceuticals worth $4.98K as of Q2 2026.
Private Wealth Asset Management left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Private Wealth Asset Management's portfolio in Q2 2026, its #788 holding.
Private Wealth Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Private Wealth Asset Management's BioMarin Pharmaceuticals position peaked at $6.15K in Q1 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Private Wealth Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.